Urovant Sciences, Inc.: Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA in Dry and Wet Overactive Bladder Populations

Post-hoc analysis indicates significant reductions in urgency episodes and micturitions in patients treated with GEMTESA vs. placebo in both types of overactive bladder (OAB) Article appears

Related Keywords

China ,Japan ,United States ,Americans ,Sumitovant Biopharma ,Sumitomo Pharma ,Salim Mujais ,Maya Frutiger ,Alana Darden Powell ,Jeffrey Frankel ,International Journal Of Clinical Practice ,Aboutsumitovant Biopharma Ltd ,Urovant Sciences Gmb ,Seattle Urology Research Center ,Sumitomo Pharma Co Ltd ,Corporate Communications ,Urovant Sciences ,Sumitovant Biopharma Ltd ,Head Of Corporate Communications ,Clinical Development ,International Journal ,Wet Overactive Bladder ,Subgroup Analysis ,Medical Director ,Seattle Urology Research ,Senior Vice President Clinical Development ,Product Information ,Urovant Sciences Gmbh ,Darden Powell ,Urovant ,Ciences ,Nnounces ,Publication ,Mpowur ,Trial ,Subgroup ,Analysis ,Showing ,Similar ,Efficacy ,Gemtesa ,Overactive ,Ladder ,Populations ,